Cemiplimab, Fianlimab Boost Chemo in Early Breast Cancer
A phase 2 clinical trial indicates that combining cemiplimab and fianlimab with standard chemotherapy improves pathologic complete response rates in patients with early-stage, HER2-negative breast cancer. The study suggests that PD-1 and LAG-3 inhibition could be a viable treatment strategy for high-risk patients.
Why it matters
Advancements in immunotherapy combinations offer hope for more effective treatment protocols for aggressive forms of breast cancer.
Cemiplimab, Fianlimab Boost Chemo in Early Breast Cancer | Mirage News
About the Study: Is combined inhibition of programmed cell death 1 protein (PD-1) and lymphocyte activation gene 3 (LAG-3) added to standard neoadjuvant chemotherapy (NAC) safe and effective in (formerly HER2)-negative early-stage breast cancer at high risk of recurrence? This phase 2 randomized clinical trial including 78 participants with -negative breast cancer found that combining cemiplimab and fianlimab with paclitaxel-based NAC improved rates of pathologic complete response in all participants, including those with triple-negative and hormone receptor positive subtypes. Patients positive for the ImPrint immune signature were highly sensitive to the combination, providing a potential biomarker of treatment response. These results indicate that combined PD-1 and LAG-3 inhibition warrants further investigation in -negative breast cancer.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in